Catalog No.
VMH02204
Species reactivity
Mouse
Host species
Mouse
Isotype
IgG
Clonality
Monoclonal
Target
Bispecific, Programmed cell death protein 1, Protein PD-1, mPD-1, CD279, Pdcd1, Pd1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, Cd274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q02242 & Q9EP73
Applications
FuncS
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0240
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade., PMID:40537244
Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609
Upregulation of PD-1 on Peripheral T cells Subsets is Associated with Parkinson's Disease., PMID:40536591
Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells., PMID:40536473
H3K36me3-Guided m6A Modification of Oncogenic L1CAM-AS1 Drives Macrophage Polarization and Immunotherapy Resistance in Hepatocellular Carcinoma., PMID:40536332
Palmitoylation-driven immune dysregulation and prognostic signature in low-grade glioma: a multi-omics and functional validation study., PMID:40535771
Case Report: Cytoreductive nephrectomy and thrombectomy in metastatic renal cell carcinoma with venous tumor thrombus: a case using indocyanine green fluorescence-guided laparoscopy., PMID:40535141
Combination of immune checkpoint inhibitors with multi-targeted tyrosine kinase inhibitors for second- or later-line therapy of non-small cell lung cancer: a systematic review and meta-analysis., PMID:40535065
Colonizable probiotic Lactobacillus paracasei R3 enhances ICI therapy via modulating PBMCs differentiation., PMID:40535013
F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies., PMID:40534867
Role of CD28+ PD-1+ Tc cells in immune response and prognosis prediction in hepatocellular carcinoma., PMID:40534863
Janus kinase and signal transducer and activator of transcription inhibitors in type 1 diabetes and immune checkpoint-related diabetes: current status and future perspectives., PMID:40534861
Treatment strategies for rapid recurrence and progression after surgery for stage I pulmonary pleomorphic carcinoma: a case report and literature review., PMID:40534846
Tissue-Resident Memory and Follicular/Peripheral Helper PD-1+ T Cells Infiltrate Lesional Skin in Atopic Dermatitis., PMID:40534582
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response., PMID:40534172
The PD-1/PD-L1 pathway and Epstein-Barr virus., PMID:40533842
Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort., PMID:40533655
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis., PMID:40532761
Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664
An evaluation of Nivolumab and ipilimumab for the treatment of resectable stage III melanoma., PMID:40531544
Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma., PMID:40531258
Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma., PMID:40531216
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-Mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis., PMID:40531080
Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers., PMID:40530506
Therapeutic potential of adenosine receptor modulators in cancer treatment., PMID:40530308
Scarring alopecia as an unexpected consequence of immune checkpoint inhibition., PMID:40530179
Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors., PMID:40529897
First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study., PMID:40529764
Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study., PMID:40529756
Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study., PMID:40529754
Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation., PMID:40529668
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study., PMID:40529375
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging., PMID:40529364
The next generation of immunotherapies for lung cancers., PMID:40528044
HAPIR: a refined Hallmark gene set-based machine learning approach for predicting immunotherapy response in cancer patients., PMID:40527973
Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer., PMID:40527175
Tumour and adipose tissue uptake on 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) predict immunotherapy response in recurrent or metastatic nasopharyngeal carcinoma., PMID:40527159
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial., PMID:40526879
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia., PMID:40526840
Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma., PMID:40522918
The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab post Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer., PMID:40522298
Acupuncture Potentiates anti-PD-1 Efficacy by Promoting CD5+ Dendritic Cells and T Cell-Mediated Tumor Immunity in a Mouse Model of Breast Cancer., PMID:40521704
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers., PMID:40521348
Boosting mRNA cancer vaccine efficacy via targeting Irg1 on macrophages in lymph nodes., PMID:40521193
Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study., PMID:40521168
Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study., PMID:40521010
Efficacy and toxicity of PD-1 inhibitor combined with induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancers., PMID:40520879
Gut microbiota is associated with the disease characteristics of patients with newly diagnosed diffuse large B-cell lymphoma., PMID:40520871
Bibliometric analysis of global research on PD-L1/PD-1 pathway and neurodegenerative diseases over the last two decades (2004-2023)., PMID:40520531
High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitors., PMID:40520330
For research use only. Not for human or drug use.
